Neogenomics Inc (NEO) Stock Price, Quote & News

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-s...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 239 768 0600

Fax: 239 690 4237

Website: www.neogenomics.com

Address:

9490 NeoGenomics Way, Fort Myers, United States

carminefox Feb. 18 at 9:09 PM

$NEO keeps beating earnings and it dips? When the buyout offer coming in?

1 · Reply

OfficialStocktwitsUser Feb. 18 at 8:01 PM

$NEO RSI: 25.25, MACD: -0.3557 Vol: 0.68, MA20: 11.92, MA50: 12.12 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Bazzzigar Feb. 18 at 5:32 PM

$NEO incompetent management

1 · Reply

d_risk Feb. 18 at 12:25 AM

$NEO - NeoGenomics Inc - 10K - Updated Risk Factors NEO’s 2026 10-K sharpens focus on operational and regulatory execution risk: new exposure from supporting sponsor trials and LIMS implementation, heightened business disruption threats, broadened business/operations and government regulation/reimbursement sections (FDA LDT oversight, ACA/PAMA/MolDx, CMS/NY remote cytology rules), intensified competition and payer friction, expanded fraud/abuse and privacy compliance risks, goodwill impairment concerns, and added risks around restructurings, M&A, and strategic investments. #HealthcareDiagnostics #RegulatoryCompliance #OperationalRisk #CompetitivePressure #MarketReimbursement 🟢 Added 🟠 Removed https://d-risk.ai/NEO/10-K/2026-02-17

0 · Reply

theDIOyears Feb. 17 at 7:29 PM

$NEO added at 9.88 Buy low sell high. Trade the volitility

0 · Reply

IN0V8 Feb. 17 at 6:58 PM

$NEO https://www.morningstar.com/news/business-wire/20260217513962/neogenomics-reports-fourth-quarter-and-full-year-2025-results

0 · Reply

IN0V8 Feb. 17 at 3:03 PM

$NEO added at $9.50

0 · Reply

Kat_Harington Feb. 17 at 2:34 PM

$NEO this stock gets beaten within an inch of its life every earnings

0 · Reply

theDIOyears Feb. 17 at 2:13 PM

$NEO Q&A brutal. What's your confidence on making your guidance?

0 · Reply

DonCorleone77 Feb. 17 at 12:43 PM

$NEO NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c Sees FY26 revenue $793M-$801M, consensus $796.7M. Sees FY26 adjusted EBITDA $55M-$57M. The company said, "Looking ahead, the imminent clinical launch of our RaDaR ST MRD assay further enhances our menu of advanced tests and allows us to address the $20+ billion molecular residual disease monitoring market. And while we anticipate modest revenue contribution from MRD in 2026, we believe the longer-term opportunity, in 2027 and beyond, is substantial. We believe RaDaR ST, together with our PanTracer family of therapy selection solutions, will be a key driver of our revenue growth over the long term. We envision a world where every cancer treatment decision is as personal as the patient, and this drives what we do every day. I am pleased with our progress in 2025 and excited about our current momentum."

0 · Reply

NeoGenomics to Participate in Upcoming Investor Conferences

Feb 17, 2026, 12:55 PM EST - 2 days ago

NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

Feb 17, 2026, 7:05 AM EST - 2 days ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 7:05 AM EST - 7 days ago

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

Jan 27, 2026, 7:05 AM EST - 23 days ago

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 25, 2026, 5:17 AM EST - 25 days ago

NeoGenomics: Distribution Moat In Community Oncology

Jan 14, 2026, 12:06 AM EST - 5 weeks ago

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:05 AM EST - 5 weeks ago

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

Jan 5, 2026, 7:05 AM EST - 6 weeks ago

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 7:05 AM EST - 7 weeks ago

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

Dec 15, 2025, 7:05 AM EST - 2 months ago

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Dec 10, 2025, 7:05 AM EST - 2 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 8, 2025, 8:05 AM EST - 2 months ago

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Nov 14, 2025, 12:41 PM EST - 3 months ago

Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 12:51 PM EDT - 4 months ago

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Oct 28, 2025, 3:11 PM EDT - 4 months ago

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:05 AM EDT - 4 months ago

NeoGenomics Reports Third Quarter 2025 Results

Oct 14, 2025, 7:05 AM EDT - 4 months ago

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

Oct 7, 2025, 7:05 AM EDT - 4 months ago

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Sep 17, 2025, 7:58 AM EDT - 5 months ago

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026

Aug 29, 2025, 1:04 PM EDT - 6 months ago

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Aug 29, 2025, 7:05 AM EDT - 6 months ago

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Aug 12, 2025, 6:56 PM EDT - 6 months ago

Neo Performance Materials Inc. (NOPMF) Q2 2025 Earnings Conference Call Transcript

Jul 30, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 29, 2025, 4:54 PM EDT - 7 months ago

NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics Reports Second Quarter 2025 Results

Jul 1, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 30, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 24, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

May 28, 2025, 7:10 AM EDT - 9 months ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 22, 2025, 7:10 AM EDT - 9 months ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 20, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics to Participate in Upcoming June Investor Conferences

May 1, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

Apr 30, 2025, 9:00 AM EDT - 10 months ago

NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)

Apr 29, 2025, 12:18 PM EDT - 10 months ago

NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 8:00 AM EDT - 10 months ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 7:30 AM EDT - 10 months ago

NeoGenomics Reports First Quarter 2025 Results

Apr 22, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 8, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

Apr 7, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics Completes Acquisition of Pathline

Apr 1, 2025, 7:05 AM EDT - 11 months ago

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

Mar 10, 2025, 7:00 AM EDT - 1 year ago

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Feb 28, 2025, 3:39 AM EST - 1 year ago

NeoGenomics: Decent Fundamentals, But Still Overvalued

Feb 18, 2025, 12:22 PM EST - 1 year ago

NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript

carminefox Feb. 18 at 9:09 PM

$NEO keeps beating earnings and it dips? When the buyout offer coming in?

1 · Reply

OfficialStocktwitsUser Feb. 18 at 8:01 PM

0 · Reply

Bazzzigar Feb. 18 at 5:32 PM

$NEO incompetent management

1 · Reply

d_risk Feb. 18 at 12:25 AM

0 · Reply

theDIOyears Feb. 17 at 7:29 PM

$NEO added at 9.88 Buy low sell high. Trade the volitility

0 · Reply

IN0V8 Feb. 17 at 6:58 PM

$NEO https://www.morningstar.com/news/business-wire/20260217513962/neogenomics-reports-fourth-quarter-and-full-year-2025-results

0 · Reply

IN0V8 Feb. 17 at 3:03 PM

$NEO added at $9.50

0 · Reply

Kat_Harington Feb. 17 at 2:34 PM

$NEO this stock gets beaten within an inch of its life every earnings

0 · Reply

theDIOyears Feb. 17 at 2:13 PM

$NEO Q&A brutal. What's your confidence on making your guidance?

0 · Reply

DonCorleone77 Feb. 17 at 12:43 PM

0 · Reply

DonCorleone77 Feb. 17 at 12:38 PM

$NEO NeoGenomics reports Q4 adjusted EPS 6c, consensus 4c Reports Q4 revenue $190.17M, consensus $188.28M. "We ended 2025 on a strong note, delivering double-digit revenue growth in the fourth quarter on the strength of our clinical volumes and ongoing mix shift toward higher value tests," stated Tony Zook, CEO of NeoGenomics. "Notably, NGS grew 23% in Q4 and 22% for the full year, both well ahead of the market growth rate, reflecting our ability to successfully pull innovation through the community channel, where we enjoy a leadership position and where approximately 80% of all cancer care is delivered today."

0 · Reply

StocktwitsEarnings Feb. 17 at 12:14 PM

$NEO Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 up 33.33% YoY • Reported revenue of $190.17M up 10.56% YoY • NeoGenomics forecasts FY 2026 consolidated revenue between $793M and $801M, representing a 9% to 10% increase from FY 2025. Adjusted EBITDA is expected to be $55M to $57M.

0 · Reply

GeeRam23 Feb. 17 at 12:08 PM

$NEO

0 · Reply

Thestocktraderhubzee Feb. 17 at 12:07 PM

$NEO NeoGenomics Q4 Adj. EPS $0.06 Beats $0.04 Estimate, Sales $190.170M Beat $188.049M Estimate

0 · Reply

GordoHLYK13 Feb. 8 at 5:46 PM

$HLYK The $HYLK Bullish Punch CEO Dr. Michael Dent is going "All-In." This filing is a massive signal of insider confidence for three key reasons: • The Ultimate Buy-In: The CEO converted $5.7M of personal advances and unpaid salary into a secured note. He’s not walking away; he’s doubling down on the company’s survival and success. • High Expectations: The conversion price is set at $4.25 per share. By locking in this price, the CEO is signaling he believes the stock is worth significantly more than its current trading level. • Balance Sheet Cleanup: He’s rolled "messy" short-term debt and old liabilities into one 3-year note, giving the company a clear runway until 2029 to execute its growth plan. The Bottom Line: The captain isn't just staying with the ship; he’s buying a bigger stake at a premium. Sec filing firm 8k released on Friday after market closed This week is bullish $TDOC $NEO

1 · Reply

DriveForShow Feb. 5 at 4:18 PM

$NEO The traditional pre-earnings dump is in full swing.

0 · Reply

YieldCurveX Feb. 4 at 1:51 PM

$NEO is a genomics company offering testing services for oncology and rare diseases; it operates in a competitive diagnostic market and faces reimbursement challenges.

0 · Reply

Estimize Feb. 4 at 11:01 AM

Wall St is expecting 0.01 EPS for $NEO Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/neo?chart=historical&metric_name=eps&utm_cont

0 · Reply

BillionerOfKing Jan. 30 at 4:48 AM

$NEO Current Stock Price: $12.42 Contracts to trade: $10 NEO Feb 20 2026 Call Entry: $1.90 Exit: $3.15 ROI: 66% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

L7_Trading Jan. 22 at 11:34 AM

$NEO Buyer 4 sol not bad

0 · Reply

GordoHLYK13 Jan. 21 at 8:17 AM

$HLYK HLYK ripping ~$4 in a week shows what can happen when real catalysts hit a thin float — moves that are fuelled by structural liquidity and fresh news, not just random hype. HealthLynked isn’t sitting still: it’s tightening up its share structure via a reverse split to boost price and support institutional interest, prepping for a Nasdaq uplist, launching its AI health assistant ‘ARI,’ expanding telemedicine & payer-integration partnerships, and locking in strategic advisors to accelerate growth. Thin float + real news = explosive potential as fundamentals and visibility start to sync. $NEO $TDOC

0 · Reply

GordoHLYK13 Jan. 15 at 2:08 PM

$HLYK HLYK is officially in 'Beast Mode' 🚀. After cleaning up the capital structure with a 1-for-100 split, the float is incredibly tight, and the market is finally pricing in the Nasdaq Uplisting coming H1 2026. With new heavy-hitter leadership from the insurance industry and a focus on AI-driven recurring revenue, HLYK isn’t just a tech play—it’s a senior exchange transition story in the making. Low float + High conviction = The perfect storm. 📈 #HLYK #NasdaqBound #HealthTech $TDOC $NEO

1 · Reply

Market Cap	1.33B
Revenue (ttm)	660.57M
Net Income (ttm)	-78.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.92%
Debt to Equity Ratio	0.00

Volume	1,528,800
Avg Vol	1,897,384
Day's Range	N/A - N/A
Shares Out	129.39M
Stochastic %K	35%
Beta	1.58
Analysts	Sell
Price Target	$14.56